Fig 4.

ZA/CG prevents high-dose HSV-2 infection. depo-treated (vaginal) or fasted (rectal) BALB/c mice were challenged with 10⁶ PFU HSV-2 10 min after application of the indicated formulations (20 animals per formulation). The aged ZA/CG (7 months at 40°C) was also applied in the vaginal study. The percentages of uninfected mice over time, based on signs of infection, are shown for each treatment group. ZA/CG gels, including the sample kept at 40°C for 7 months, are significantly more protective than CG (P < 0.0001 for vaginal data and P = 0.03 for rectal data) or D-PBS (P < 0.0001 for vaginal data and P = 0.008 for rectal data).